Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 54 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Trastuzumab deruxtecan for treating HER2-low, HR-positive, metastatic breast cancer	Trastuzumab deruxtecan (DS-8201a; Enhertu)	Breast cancer	Breast Cancer	2022	View \| Download
Trastuzumab deruxtecan for metastatic HER2 - positive breast cancer – second line	Trastuzumab deruxtecan (DS-8201a; Enhertu)	Breast cancer	Breast Cancer	2020	View \| Download
Trastuzumab deruxtecan for HER2-positive metastatic or unresectable breast cancer	Trastuzumab deruxtecan (DS-8201a; Enhertu)	Breast cancer	Breast Cancer	2019	View \| Download
Taselisib in Combination with Fulvestrant for Advanced ER Positive, HER2-negative Breast Cancer – Second Line After Aromatase Inhibitor Therapy	Fulvestrant (Faslodex) , Taselisib (GDC-0032; RG-7604)	Breast cancer	Breast Cancer	2017	View \| Download
Sacituzumab govitecan for treating previously untreated locally advanced or metastatic triple negative breast cancer with negative PD-L1 status	Sacituzumab Govitecan (IMMU-132; Trodelvy)	Breast cancer	Breast Cancer	2023	View \| Download
Sacituzumab govitecan for treating HR+/HER2- negative metastatic breast cancer	Sacituzumab Govitecan (IMMU-132; Trodelvy)	Breast cancer	Breast Cancer	2021	View \| Download
Sacituzumab govitecan for metastatic or unresectable locally advanced triple-negative breast cancer – third line	Sacituzumab Govitecan (IMMU-132; Trodelvy)	Breast cancer	Breast Cancer	2021	View \| Download
Rucaparib with nivolumab for the maintenance treatment of newly diagnosed epithelial ovarian, fallopian tube, or primary peritoneal cancer	Nivolumab (Opdivo; BMS-936558; ONO-4538) , Rucaparib (Rubraca; PF-1367338)	Breast cancer	Breast Cancer	2022	View \| Download
Ribociclib with endocrine therapy for HR+/HER2- early breast cancer – adjuvant treatment	Endocrine therapy , Ribociclib (Kisqali; LEE-011; ribociclib succinate)	Breast cancer	Breast Cancer	2022	View \| Download
Ribociclib and Fulvestrant and PI3K Inhibitor (Buparlisib or Alpelisib) for HR Positive, HER2 Negative Postmenopausal Breast Cancer – Second or Third Line	Alpelisib (BYL719; Piqray) , Fulvestrant (Faslodex) , Ribociclib (Kisqali; LEE-011; ribociclib succinate)	Breast cancer	Breast Cancer	2017	View \| Download